

NAME:	1G5/LTR – Luciferase cells
REPOSITORY REFERENCE:	ARP5010
CELL TYPE:	Jurkat derivative
PROPAGATION MEDIUM:	RPMI 1640, 90%; Foetal calf serum, 10%
FREEZE MEDIUM:	RPMI 1640, 72.5% Foetal calf serum, 20% DMSO, 7.5%
GROWTH CHARACTERISTICS:	1G5 cells should be maintained at $<10^6$ cells/ml. Doubling time is approximately 24 hours. Split 1:10 every five days. The cells grow in suspension as single cells or small clumps. The suggested medium for 1G5 cells is RPMI with 10% fetal bovine serum; however, 1G5 cells have also been grown in RPMI with 5% fetal bovine serum and DMEM with 10% fetal bovine serum without appreciable change in their characteristics.
MORPHOLOGY:	Characteristic T cell appearance; round, refractile with smooth edges.
SPECIAL CHARACTERISTICS:	1G5 is a Jurkat derivative containing a stably integrated HIV-LTR-luciferase construct. Cells were selected for low basal luciferase activity, HIV infectability, high responsiveness to <i>tat</i> expression, and high responsiveness to T-cell activation signals. Conditions can be established for quantitative analysis of LTR (HIV)-luciferase response to each of these conditions. A 10-1000-fold increase in luciferase activity can be achieved after transfection or infection of 1G5 with <i>tat</i> -expressing vectors or HIV. Equivalent levels of expression have also been detected after stimulation with T cell mitogens and stimulating environmental conditions. When used in conjunction with a <i>tat</i> -expressing vector, 1G5 provides a system for testing potential anti- <i>tat</i> therapies without the use of live HIV.

- STORAGE:** Liquid Nitrogen
- SOURCE:** Dr Estuardo Aguilar-Cordova and Dr. John Belmont (courtesy of NIH AIDS Research and Reference Reagent Programme.)
- REFERENCE:** Aguilar-Cordova E, Chinen J, Donehower L, Lewis DE, Belmont JW. A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. *AIDS Res Hum Retroviruses* **10**:295-301, 1994
- ACKNOWLEDGEMENTS:** Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the "Acknowledgements" section.
Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)
- NOTE:** Corporate requests should be directed to Dr. Aguilar-Cordova or Dr. Belmont, Baylor College of Medicine, Institute for Molecular Genetics, One Baylor Plaza, Houston, TX77030

HIV-TAT DRUG INTERACTION STUDIES USING 1G5 CELLS

Cell Culture and transfection:

1G5 cells were maintained in RPMI 1640 supplemented with 10% HyClone fetal calf serum. Transfections were done in complete medium in a BTX electroporator at 120 V, 3000 μ F, in 125 μ l at 2.5×10^7 cells/ml in a 0.2ml cuvette. Infections with retroviral vectors were done by supernatant exposure in complete medium containing 4.0 μ g/ml polybrene. HIV infections using the NL4-3 laboratory strain were performed in complete medium. The infected cells were then treated with anti-viral compounds.

Luciferase Analysis

Five days after infection with HIV or a Tat retroviral vector (E. Aguilar-Cordova, unpublished data) and exposure to antiviral compounds, the cells were harvested, centrifuged at 1800 rpm for two minutes, washed once with PBS, and resuspended in 50 μ l of luciferase lysis buffer [25 mM Tris-phosphate (ph 7.8), 2mM 1, 2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol, 1% Triton X-100]. The mixture was incubated at room temperature for 15-30 minutes and microfuged for 30 seconds. 10 μ l of the lysis supernatant was added to 50 μ l of luciferase assay reagent (Promega) and immediately read in a Packard scintillation counter set for single photon counting. All experiments were done in triplicate.